Form 8-K - Current report:
SEC Accession No. 0000950170-25-063514
Filing Date
2025-05-05
Accepted
2025-05-05 16:02:39
Documents
13
Period of Report
2025-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sndx-20250505.htm   iXBRL 8-K 50477
2 EX-99.1 sndx-ex99_1.htm EX-99.1 205910
3 GRAPHIC img199102934_0.jpg GRAPHIC 14374
  Complete submission text file 0000950170-25-063514.txt   407293

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sndx-20250505.xsd EX-101.SCH 24852
15 EXTRACTED XBRL INSTANCE DOCUMENT sndx-20250505_htm.xml XML 4682
Mailing Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017
Business Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 25912781
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)